Patient advocacy groups should disclose pharma sponsors, say experts

By Kate Aubusson
Updated February 4 2017 - 11:13am, first published January 18 2017 - 8:14am
Professor Lisa Bero warns that patient advocacy groups may be influenced by big pharma money. Photo: University of Sydney
Professor Lisa Bero warns that patient advocacy groups may be influenced by big pharma money. Photo: University of Sydney
Dr Ray Moynihan is pushing for greater transparency over the partnerships between patient advocacy groups and their commercial backers.  Photo: Supplied
Dr Ray Moynihan is pushing for greater transparency over the partnerships between patient advocacy groups and their commercial backers. Photo: Supplied

Patient advocacy groups should be forced to declare their commercial funding, with a growing body of evidence raising serious concerns over conflicts of interests, Australian experts say.

Subscribe now for unlimited access.

$0/

(min cost $0)

or signup to continue reading

See subscription options

Get the latest Glen Innes news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.